Capital Fund Management (CFM)’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.6M | Sell |
25,700
-23,600
| -48% | -$12.8M | 0.06% | 464 |
|
|
2025
Q4 | $28.6M | Sell |
49,300
-102,700
| -68% | -$58.1M | 0.08% | 342 |
|
|
2025
Q3 | $73.7M | Sell |
152,000
-22,200
| -13% | -$10.3M | 0.19% | 107 |
|
|
2025
Q2 | $70.6M | Buy |
+174,200
| New | +$72.8M | 0.19% | 120 |
|
|
2024
Q4 | – | Sell |
-12,500
| Closed | -$7.73M | – | 2252 |
|
|
2024
Q3 | $7.73M | Buy |
+12,500
| New | +$7.4M | 0.02% | 821 |
|
|
2024
Q2 | – | Sell |
-32,000
| Closed | -$18.6M | – | 2171 |
|
|
2024
Q1 | $18.6M | Sell |
32,000
-50,900
| -61% | -$28.6M | 0.05% | 477 |
|
|
2023
Q4 | $44M | Buy |
+82,900
| New | +$40.1M | 0.12% | 237 |
|
|
2023
Q3 | – | Sell |
-23,200
| Closed | -$12.1M | – | 2094 |
|
|
2023
Q2 | $12.1M | Buy |
+23,200
| New | +$12.5M | 0.05% | 498 |
|
|
2022
Q2 | – | Sell |
-28,400
| Closed | -$16.8M | – | 1649 |
|
|
2022
Q1 | $16.8M | Buy |
28,400
+9,900
| +54% | +$5.69M | 0.14% | 209 |
|
|
2021
Q4 | $12.3M | Sell |
18,500
-5,200
| -22% | -$3.25M | 0.09% | 308 |
|
|
2021
Q3 | $13.5M | Sell |
23,700
-1,100
| -4% | -$604K | 0.1% | 276 |
|
|
2021
Q2 | $12.5M | Buy |
+24,800
| New | +$11.7M | 0.1% | 266 |
|
|
2021
Q1 | – | Sell |
-28,000
| Closed | -$13M | – | 1603 |
|
|
2020
Q4 | $13M | Buy |
+28,000
| New | +$13.1M | 0.12% | 198 |
|
|
2019
Q4 | – | Sell |
-3,700
| Closed | -$1.08M | – | 2038 |
|
|
2019
Q3 | $1.08M | Sell |
3,700
-26,200
| -88% | -$7.5M | 0.01% | 992 |
|
|
2019
Q2 | $8.78M | Buy |
29,900
+22,600
| +310% | +$6.22M | 0.08% | 334 |
|
|
2019
Q1 | $2M | Buy |
7,300
+5,400
| +284% | +$1.34M | 0.02% | 810 |
|
|
2018
Q4 | $425K | Sell |
1,900
-9,100
| -83% | -$2.14M | ﹤0.01% | 1453 |
|
|
2018
Q3 | $2.69M | Buy |
+11,000
| New | +$2.53M | 0.01% | 993 |
|
|
2018
Q1 | – | Sell |
-1,800
| Closed | -$342K | – | 2177 |
|
|
2017
Q4 | $342K | Sell |
1,800
-200
| -10% | -$38.3K | ﹤0.01% | 1580 |
|
|
2017
Q3 | $378K | Buy |
+2,000
| New | +$362K | ﹤0.01% | 1262 |
|
|
2016
Q1 | – | Sell |
-7,100
| Closed | -$1.01M | – | 1836 |
|
|
2015
Q4 | $1.01M | Buy |
+7,100
| New | +$947K | 0.01% | 882 |
|
|
2014
Q4 | – | Sell |
-3,000
| Closed | -$365K | – | 1801 |
|
|
2014
Q3 | $365K | Sell |
3,000
-24,900
| -89% | -$3.03M | ﹤0.01% | 1253 |
|
|
2014
Q2 | $3.29M | Buy |
27,900
+13,700
| +96% | +$1.61M | 0.03% | 555 |
|
|
2014
Q1 | $1.71M | Buy |
14,200
+4,600
| +48% | +$547K | 0.02% | 749 |
|
|
2013
Q4 | $1.07M | Buy |
+9,600
| New | +$955K | 0.01% | 956 |
|
|
2013
Q3 | – | Sell |
-4,700
| Closed | -$398K | – | 1896 |
|
|
2013
Q2 | $398K | Buy |
+4,700
| New | +$391K | 0.01% | 1061 |
|
Other funds holding TMO
VCM
Capital Fund Management (CFM)'s TMO Position: Q1 2026 in Review
Capital Fund Management (CFM) opened a new position in Thermo Fisher Scientific (TMO) in Q1 2026: 22,205 shares worth $10.9M. The stake represents 0.05% of the portfolio and ranks #518 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in TMO as recently as Q2 2025.
Capital Fund Management (CFM) first reported a position in TMO in Q1 2014 and has held it in 14 quarters since. The position peaked at $53.5M in Q2 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Capital Fund Management (CFM) held 22,205 shares of Thermo Fisher Scientific worth $10.9M as of Q1 2026.
- Thermo Fisher Scientific was a new Capital Fund Management (CFM) position in Q1 2026.
- Thermo Fisher Scientific made up 0.05% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #518 holding.
- Capital Fund Management (CFM) first reported a position in Thermo Fisher Scientific in Q1 2014 and has held it in 14 quarters since.
- Capital Fund Management (CFM)'s Thermo Fisher Scientific position peaked at $53.5M in Q2 2025.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.